Information Provided By: 
Fly News Breaks for May 23, 2019
ZTS
May 23, 2019 | 07:21 EDT
Guggenheim analyst David Westenberg initiated coverage on 10 companies in animal health, starting Zoetis with a Buy rating and $114 price target. He believes Zoetis' current "big three" of Simparica, CYTOPOINT, and Apoquel will allow it to meet near-term growth targets and thinks the company should see significant growth from new products in pain and parasiticides that are currently underappreciated.
News For ZTS From the Last 2 Days
